An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai
Currently, there is no treatment that slows the progression of the disease, which is the leading cause of vision loss in people over 65.
“This is the first study to show preservation of vision after a single injection of adult-derived human cells into a rat model with age-related macular degeneration,” said Shaomei Wang, MD, PhD, lead author of the study published in the journal STEM CELLS and a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute.
The stem cell injection resulted in 130 days of preserved vision in laboratory rats, which roughly equates to 16 years in humans.
Age-related macular degeneration affects upward of 15 million Americans. It occurs when the small central portion of the retina, known as the macula, deteriorates. The retina is the light-sensing nerve tissue at the back of the eye. Macular degeneration may also be caused by environmental factors, aging and a genetic predisposition.
When animal models with macular degeneration were injected with induced neural progenitor stem cells, which derive from the more commonly known induced pluripotent stem cells, healthy cells began to migrate around the retina and formed a protective layer. This protective layer prevented ongoing degeneration of the vital retinal cells responsible for vision.
Cedars-Sinai researchers in the Induced Pluripotent Stem Cell (iPSC) Core, directed by Dhruv Sareen, PhD, with support from the David and Janet Polak Foundation Stem Cell Core Laboratory, first converted adult human skin cells into powerful induced pluripotent stem cells (iPSC), which can be expanded indefinitely and then made into any cell of the human body. In this study, these induced pluripotent stem cells were then directed toward a neural progenitor cell fate, known as induced neural progenitor stem cells, or iNPCs.
“These induced neural progenitor stem cells are a novel source of adult-derived cells which should have powerful effects on slowing down vision loss associated with macular degeneration,” said Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and contributing author to the study. “Though additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.”
The Latest on: Age-Related Macular Degeneration
via Google News
The Latest on: Age-Related Macular Degeneration
- Coronavirus and eye disease: What older people should knowon March 24, 2020 at 3:17 am
At the American Macular Degeneration Foundation (AMDF) we have been thinking a lot about how many of you in the age-related macular degeneration (AMD) community may be concerned about being more ...
- A tooth-enamel protein is found in eyes with a common form of macular degenerationon March 23, 2020 at 5:05 am
Deposits of a mineral found in tooth enamel at the back of the eye could be hastening the progression of age-related macular degeneration, the leading cause of deteriorating eyesight in people over 50 ...
- Choriocapillaris flow impairment could predict the enlargement of geographic atrophy lesionon March 22, 2020 at 2:30 pm
Aim To analyse the choriocapillaris (CC) flow status in the area that subsequently showed geographic atrophy (GA) expansion secondary to age-related macular degeneration (AMD) during 1-year follow-up, ...
- Researchers discover tooth-enamel protein in eyes with dry AMDon March 22, 2020 at 8:56 am
A protein that normally deposits mineralized calcium in tooth enamel may also be responsible for calcium deposits in the back of the eye in people with dry age-related macular degeneration (AMD), ...
- Enrollment complete in Graybug’s phase 2b wet AMD treatment trialon March 20, 2020 at 11:17 am
The final patient has been enrolled in a phase 2b trial of Graybug Vision’s wet age-related macular degeneration treatment candidate, according to a press release. The multicenter, prospective, masked ...
- Visual acuity, injection frequency decrease over time in real-world AMD studyon March 19, 2020 at 2:33 pm
In a retrospective study, patients with neovascular age-related macular degeneration treated with anti-VEGF injections experienced decreased visual acuity from baseline and decreased number of ...
- FDA Says No To Epilepsy Drug, IMV Advances COVID-19 Vaccine, ISEE Delays Studyon March 18, 2020 at 10:23 pm
(RTTNews) - Today's Daily Dose brings you news about the FDA rejecting Eton Pharma's Lennox-Gastaut syndrome drug, the progress in IMV's COVID-19 vaccine program, delay in IVERIC bio's dry age-related ...
- RIBOMIC Enters License Agreement with AJU Pharma for RBM-007 in Age-related Macular Degenerationon March 17, 2020 at 5:05 pm
RIBOMIC has signed the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company for RBM-007 licensing agreement.
- BRIEF-Ribomic Enters License Agreement With Aju Pharma For Rbm-007 In Age-Related Macular Degenerationon March 17, 2020 at 3:34 pm
* RIBOMIC - UPON EXECUTION OF AGREEMENT, AJU WILL OBTAIN EXCLUSIVE LICENSE TO DEVELOP AND SELL PRODUCT CONTAINING RBM-007 IN TERRITORY * RIBOMIC - WILL RECEIVE AN UPFRONT PAYMENT OF US$1 MILLION AND I ...
- Wet Age-related Macular Degeneration Market analysis and forecaston March 16, 2020 at 8:32 am
Wet Age-related Macular Degeneration Market (wET AMD mARKET) is fuelling due to the launch of novel therapies and increasing Wet AMD incidence population. DelveInsight's Wet AMD market report proffers ...
via Bing News